Korean startup MediThinQ has announced the launch of its SCOPEYE 3D Micro Surgery Solution, which uses the latest Eyes Up Display technology for improving precision across medical specialties.
The solution includes the SCOPEYE Eyes Up wearable display, the light and portable 3D digital microscope 3D Microvision, and the 3D AddON device.
Related: Laborie launches Solar Compact System and manometry catheter
These features work in concert to provide surgeons with high-resolution 3D optics, improving depth perception and spatial awareness without the need for traditional eyepieces.
The SCOPEYE 3D Micro Surgery Solution’s portability and space-saving features make it suitable for a wide array of medical procedures, including microsurgery, dental procedures, plastic surgery, ophthalmology, hair transplant surgery, and dermatology.
Furthermore, MediThinQ has named VentureBlick founder and CEO Chris Lee as chairman of the company’s board.
Lee has 30 years of experience in leadership roles with top global pharmaceutical and medtech companies.
MediThinQ has also signed a cross-ownership agreement with VentureBlick whereby both entities will hold shares in one another.
The partnership between MediThinQ and VentureBlick began with MediThinQ’s participation in the Super Incubator programme.
Lee said: “MediThinQ’s solutions deliver tangible medical value, and we are thrilled to collaborate with them on an even deeper level to enhance surgical visualisation, ultimately leading to improved patient outcomes.
“Our partnership will accelerate MediThinQ’s growth further and pave the way for pioneering advancements in the field of extended reality for surgical applications.”
With the guidance of VentureBlick, MediThinQ has reached significant milestones and is now poised for further expansion.
Currently, MediThinQ is raising funds for its Series B round and is considering various initial public offering options in Asia and North America.
The company is also exploring the possibility of early exits through strategic acquisitions or rapid commercial growth.
